Fundraising FoxTheraCryf
1 known investors
Find your way into TheraCryf
Sign up to see every warm intro you have to TheraCryf
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TheraCryf team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TheraCryf is developing Ox-1, a candidate-stage orexin-1 receptor antagonist molecule intended to treat substance use disorders (addictive behaviours) and anxiety. The compound is at late pre-clinical stage and funded toward regulatory submissions for Phase 1 human volunteer studies.
Investors · 1
Funding
SEC filings, press & company announcements- Undisclosed amountPlacing & SubscriptionAug 2026Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does TheraCryf do?
- TheraCryf is developing Ox-1, a candidate-stage orexin-1 receptor antagonist molecule intended to treat substance use disorders (addictive behaviours) and anxiety. The compound is at late pre-clinical stage and funded toward regulatory submissions for Phase 1 human volunteer studies.
- Who are TheraCryf's investors?
- TheraCryf's investors include Seneca Partners.